BR9811094A - Agente terapêutico para tumores linfáticos - Google Patents

Agente terapêutico para tumores linfáticos

Info

Publication number
BR9811094A
BR9811094A BR9811094-2A BR9811094A BR9811094A BR 9811094 A BR9811094 A BR 9811094A BR 9811094 A BR9811094 A BR 9811094A BR 9811094 A BR9811094 A BR 9811094A
Authority
BR
Brazil
Prior art keywords
therapeutic agent
lymphatic tumors
lymphatic
tumors
seq
Prior art date
Application number
BR9811094-2A
Other languages
English (en)
Inventor
Yasuo Koishihara
Yasushi Yoshimura
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BR9811094A publication Critical patent/BR9811094A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Patente de Invenção: <B>"AGENTE TERAPêUTICO PARA TUMORES LINFáTICOS"<D>. Um agente terapêutico para tumores linfáticos (excluindo mieloma) compreendendo como um ingrediente ativo um anticorpo que liga-se especificamente a uma proteína tendo a seq³ência de aminoácidos como mostrada em SEQ ID NO: 1 e que tem uma atividade citotóxica.
BR9811094-2A 1997-02-12 1998-02-12 Agente terapêutico para tumores linfáticos BR9811094A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4141097 1997-02-12
PCT/JP1998/000568 WO1998035698A1 (en) 1997-02-12 1998-02-12 Remedies for lymphocytic tumors

Publications (1)

Publication Number Publication Date
BR9811094A true BR9811094A (pt) 2000-07-18

Family

ID=12607597

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811094-2A BR9811094A (pt) 1997-02-12 1998-02-12 Agente terapêutico para tumores linfáticos

Country Status (19)

Country Link
US (2) US6503510B2 (pt)
EP (1) EP0997152B1 (pt)
KR (2) KR100655979B1 (pt)
CN (1) CN1191855C (pt)
AT (1) ATE297219T1 (pt)
AU (1) AU724133B2 (pt)
BR (1) BR9811094A (pt)
CA (1) CA2280875C (pt)
DE (1) DE69830492T2 (pt)
ES (1) ES2241114T3 (pt)
HU (1) HUP0001136A3 (pt)
IL (1) IL131381A0 (pt)
NO (1) NO993866L (pt)
PL (1) PL190065B1 (pt)
RU (1) RU2177805C2 (pt)
SK (1) SK110099A3 (pt)
TR (1) TR199901949T2 (pt)
UA (1) UA65561C2 (pt)
WO (1) WO1998035698A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW474991B (en) * 1993-10-15 2002-02-01 Toshio Hirano Membrane protein polypeptide having function of pre-B cell proliferation and the encoded gene thereof
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
EP1059533A4 (en) * 1998-02-25 2005-02-09 Chugai Pharmaceutical Co Ltd METHOD FOR THE IMMUNOLOGICAL DETECTION OF ANTI-HM1.24 ANTIBODY
ATE404216T1 (de) 1999-08-23 2008-08-15 Chugai Pharmaceutical Co Ltd Verstärker der hm1.24 antigen-expression
WO2002057316A1 (en) 2000-12-28 2002-07-25 Kirin Beer Kabushiki Kaisha Novel monoclonal antibody
JP3986439B2 (ja) 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
EP3088412B1 (en) 2001-03-09 2021-05-05 Chugai Seiyaku Kabushiki Kaisha Protein purification method
US7888478B2 (en) 2002-09-11 2011-02-15 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US7858330B2 (en) 2001-10-19 2010-12-28 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20050226869A1 (en) * 2001-10-19 2005-10-13 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
EP3192528A1 (en) * 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
WO2003072068A2 (en) * 2002-02-27 2003-09-04 University Of South Carolina Targeted immunotherapy of acute lymphoblastic leukemia (all)
US20080219974A1 (en) * 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
JP4462964B2 (ja) * 2003-03-10 2010-05-12 第一三共株式会社 癌特異的抗原を標的とした抗体
US20070142627A1 (en) * 2003-08-01 2007-06-21 Chugai Seiyaku Kabushiki Kaisha Sugar-chain-altered anti-hm1.24 antibody
EP1693069B1 (en) * 2003-10-10 2013-07-24 Chugai Seiyaku Kabushiki Kaisha Remedy for solid tumor
AU2005297772B2 (en) * 2004-10-26 2011-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having modified sugar chain
US20080299128A1 (en) * 2006-06-20 2008-12-04 Myung Kim Effect of Bst2 on inflammation
US8329186B2 (en) 2004-12-20 2012-12-11 Isu Abxis Co., Ltd Treatment of inflammation using BST2 inhibitor
CN1865275B (zh) * 2005-05-17 2011-06-15 长春华普生物技术有限公司 对人b细胞肿瘤有治疗作用的人工合成的单链脱氧核苷酸
BRPI0613382A8 (pt) * 2005-06-20 2018-01-02 Genentech Inc anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
CA2660795C (en) * 2006-09-18 2014-11-18 Xencor, Inc. Optimized antibodies that target hm1.24
AU2008312858A1 (en) 2007-10-16 2009-04-23 Sbi Biotech Co., Ltd. Anti-BST2 antibody
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
US9123149B2 (en) * 2013-03-15 2015-09-01 Columbia Insurance Company Expert color system for color selection with color harmony and color emotion intelligence
CN107619443B (zh) * 2016-07-14 2020-08-14 深圳宾德生物技术有限公司 抗人和鼠cd317的单克隆抗体及其制备方法和应用
CN109748964B (zh) * 2017-11-01 2020-11-17 深圳宾德生物技术有限公司 CD317单链抗体317scFv、其编码序列及制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
ES2134212T3 (es) * 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
TW474991B (en) * 1993-10-15 2002-02-01 Toshio Hirano Membrane protein polypeptide having function of pre-B cell proliferation and the encoded gene thereof
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
KR100370744B1 (ko) * 1997-02-28 2003-02-05 츄가이 세이야꾸 가부시키가이샤 임파구의 활성화 억제제
CA2305712A1 (en) * 1997-10-03 1999-04-15 Chugai Seiyaku Kabushiki Kaisha Natural humanized antibody
AU732306B2 (en) * 1997-10-14 2001-04-12 Chugai Seiyaku Kabushiki Kaisha Potentiator for antibody against lymphoid tumor

Also Published As

Publication number Publication date
US6503510B2 (en) 2003-01-07
EP0997152A1 (en) 2000-05-03
TR199901949T2 (xx) 2000-01-21
CN1191855C (zh) 2005-03-09
EP0997152A4 (en) 2001-04-18
ES2241114T3 (es) 2005-10-16
RU2177805C2 (ru) 2002-01-10
DE69830492T2 (de) 2006-03-16
US20020037288A1 (en) 2002-03-28
SK110099A3 (en) 2000-08-14
ATE297219T1 (de) 2005-06-15
UA65561A (en) 2000-08-15
AU5956398A (en) 1998-09-08
HK1026368A1 (en) 2000-12-15
CA2280875C (en) 2005-07-05
NO993866D0 (no) 1999-08-11
PL190065B1 (pl) 2005-10-31
IL131381A0 (en) 2001-01-28
NO993866L (no) 1999-10-11
HUP0001136A3 (en) 2002-02-28
CN1250381A (zh) 2000-04-12
US20030113334A1 (en) 2003-06-19
KR20030097614A (ko) 2003-12-31
UA65561C2 (uk) 2004-04-15
CA2280875A1 (en) 1998-08-20
DE69830492D1 (de) 2005-07-14
HUP0001136A2 (hu) 2000-08-28
KR20000070989A (ko) 2000-11-25
EP0997152B1 (en) 2005-06-08
KR100655979B1 (ko) 2006-12-08
PL335140A1 (en) 2000-04-10
WO1998035698A1 (en) 1998-08-20
AU724133B2 (en) 2000-09-14

Similar Documents

Publication Publication Date Title
EP0997152A4 (en) MEDICINE AGAINST LYMPHATIC TUMORS
DE69910216D1 (de) Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
BR0109272A (pt) Agentes conjugados terapêuticos de ácido poliglutâmico, métodos para suas preparações e usos
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
PT1131065E (pt) Fumaratos dialquilicos para o tratamento de doencas autoimunes
NO20025450D0 (no) Ny farmasöytisk sammensetning
TR199802423T2 (xx) Konsantre antikor terkibi.
BRPI0113331B8 (pt) derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica
BR0210056A (pt) composições e métodos para tratamento de hiperplasia
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
BR9914631A (pt) Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades
PT1071433E (pt) 2&#39;,2&#39;-difluoronuecleosidos para terapia imunossupressora e preparados farmaceuticos combinados
PT975334E (pt) Microparticulas biodegradaveis para a libertacao sustentada de farmacos terapeuticos
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
PT1079849E (pt) Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica
BR0014758A (pt) Sistemas e métodos para expressão de proteìna com alto rendimento
BR9912223A (pt) Agente terapêutico para crise hipercalcêmica
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
WO2002058589A3 (en) Agents and methods for promoting bone growth
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
DE60125232D1 (de) Kleines säurelösliches sporenprotein und seine verwendungen
BR9810433A (pt) Composições anti-helmìnticas
PT983300E (pt) Sais peptidicos de bpc com actividade organo-protectora, processo para a sua preparacao e sua utilizacao em terapia
BR0011845A (pt) Complexo farmacêutico

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.